No products in the cart.
Pre-made Bamlanivimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-045
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.
| Products Name (INN Index) | Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody |
|---|---|
| INN Name | Bamlanivimab |
| Target | SARS-CoV-2 Spike |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 7l3n:DE/7kmg:AB:DE |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Abcellera,Eli Lilly and Company,National Institute of Allergy and Infectious Diseases |
| Conditions Approved | COVID-19 |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Baiting from convalescent human B-cells |
| Previous Name | NA |
| Gm Offical Target Name | SARS-CoV-2 Spike |
| Package |
Previous slide
Next slide
